Assessment of effective absorbed dose of 111in-DTPA-buserelin in human on the basis of biodistribution rat data

Radiation Protection Dosimetry

Volumn 154, Issue 1, 2013, Pages 1-8

  Lahooti, Afsaneh ^a   Shanehsazzadeh, Saeed ^a   Jalilian, Amir Reza ^b   Tavakoli, Mohammad Bagher ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Research Institute   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CHELATING AGENT; DIAGNOSTIC AGENT; FERTILITY PROMOTING AGENT; INDIUM; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL MODEL; COMPARATIVE STUDY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; RADIATION DOSE; RADIOMETRY; RAT; TISSUE DISTRIBUTION;

ANIMALS; BUSERELIN; CHELATING AGENTS; FERTILITY AGENTS, FEMALE; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRA-ARTERIAL; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PENTETIC ACID; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; RATS; TISSUE DISTRIBUTION;

EID: 84875634351     PISSN: 01448420     EISSN: 17423406     Source Type: Journal    
DOI: 10.1093/rpd/ncs137     Document Type: Article

References (37)

1. Schally, A. V., Arimura, A., Baba, Y., Nair, R. M., Matsuo, H., Redding, T. W. and Debeljuk, L. Isolation and properties of the FSH and LH-releasing hormone. Biochem. Biophys. Res. Commun. 43, 393-399 (1971).
2. Baba, Y., Matsuo, H. and Schally, A. V. Structure of the porcine LH-and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochem. Biophys. Res. Commun. 44, 459-463 (1971).
3. Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T. A., Comaruschally, A. M. and Schally, A. V. Tumor-growth inhibition in patients with prostatic-carcinoma treated with luteinizing-hormone-releasing hormone agonists. Proc. Natl Acad. Sci. USA Biol. Sci. 79, 1658-1662 (1982).
4. Klijn, J. G. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med. Oncol. Tumor Pharmacother. 1, 123-128 (1984).
5. Jalilian, A., Shanehsazzadeh, S., Akhlaghi, M., Garousi, J., Rajabifar, S. and Tavakoli, M. Preparation and biodistribution of [Ga-67]-DTPA-gonadorelin in normal rats. J. Radioanal. Nucl. Chem. 278, 123-129 (2008).
6. Jalilian, A. R., Shanehsazzadeh, S., Akhlaghi, M., Kamali-dehghan, M. and Moradkhani, S. Development of [(111)In]-DTPA-buserelin for GnRH receptor studies. Radiochim. Acta 98, 113-119 (2010).
7. Khorrami Moghaddam, A. R., Jalilian, A., Hayati, V. and Shanehsazzadeh, S. Determination of human absorbed dose of 201Tl(III)-DTPA-HIgG based on biodistribution data in rats. Radiat. Prot. Dosim. 141, 269-274 (2010).
8. DeGrado, T. R., Baldwin, S. W., Wang, S. Y., Orr, M. D., Liao, R. P., Friedman, H. S., Reiman, R., Price, D. T. and Coleman, R. E. Synthesis and evaluation of F-18-labeled choline analogs as oncologic PET tracers. J. Nucl. Med. 42, 1805-1814 (2001).
9. Santens, P., De Vos, F., Thierens, H., Decoo, D., Slegers, G., Dierckx, R. A. and De Reuck, J. Biodistribution and dosimetry of carbon-11-methoxyprogabidic acid, a possible ligand for GABA-receptors in the brain. J. Nucl. Med.: Official Publication. Soc. Nucl. Med. 39, 307-310 (1998).
10. Biological Council. Guidelines on the Use of Living Animals in Scientific Investigations. Biological Council (1987) ISBN 0950021326.
11. Mirzaei, M., Afarideh, H., Haji-Saeid, S. M. and Ardaneh, K. Production of In-111 by irradiation of natural cadmium with deuterons and protons in NRCAM cyclotron. Cyclot. Appl. 1999, 65-67 (1998).
12. Marczenko, Z. Spectrophotometric Determination of Elements. Spectrophotometric Determination of Elements. John Wiley & Sons Inc., pp. 176-179 (1976).
13. Hnatowich, D. J., Layne, W. W., Childs, R. L., Lanteigne, D., Davis, M. A., Griffin, T. W. and Doherty, P. W. Radioactive labeling of antibody: a simple and efficient method. Science 220, 613-615 (1983).
14. Shanehsazzadeh, S., Lahooti, A., Sadeghi, H. R. and Jalilian, A. R. Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data. Nucl. Med. Commun. 32, 37-43 (2011).
15. Shanehsazzadeh, S., Jalilian, A. R., Sadeghi, H. R. and Allahverdi, M. Determination of human absorbed dose of 67GA-DTPA-ACTH based on distribution data in rats. Radiat. Prot. Dosim. 134, 79-86 (2009).
16. Snyder, W., Ford, M., Warner, G. and Watson, S. S. Absorbed dose per unit cumulated activity for selected radionuclides and organs. In: Society of Nuclear Medicine. MIRD, Ed. (1975).
17. Snyder, W. S., Ford, M. R. and Warner, G. G. Committee SoNMMIRD. Estimates of specific absorbed fractions for photon sources: uniformly distributed in various organs of a heterogeneous phantom. Society of Nuclear Medicine New York (1978).
18. ICRU. Methods and assessment of absorbed dose in clinical use of radionuclides. ICRU Report 32. International Commission on Radiation Units and Measurements (1979).
19. NCRPM. The experimental basis for absorbed dose calculations in medical uses of radionuclides. Report No. 83. National Council on Radiation Protection and Measurements. (1985).
20. Loevinger, R., Budinger, T. F. and Watson, E. E. MIRD Primer for Absorbed Dose Calculations. Society of Nuclear Medicine New York (1988).
21. International Commission on Radiological Protection. Radiological protection in biomedical research. ICRP Publication 62. Annals of ICRP. Permagon Press (1992).
22. Siegel, J. A. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother. Radiopharm. 20, 126-40 (2005).
23. Kirschner, A. S., Ice, R. D. and Beierwaltes, W. H. Radiation dosimetry of 131I-19-iodocholesterol. J. Nucl. Med.: Official Publication. Soc. Nucl. Med. 14, 713-717 (1973).
24. Sparks, R. B. and Aydogan, B. (eds). Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. In: Sixth International Radiopharmaceutical Dosimetry Symposium. USA: Oak Ridge Associated Universities (1999).
25. Cristy, M. and Eckerman, K. Specific Absorbed Fractions of Energy at Various Ages from Internal Photons Sources. Oak Ridge National Laboratory (1987).
26. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. ICRP Publication 23. Pergamon Press (1993).
27. Bacher, K. and Thierens, H. M. Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine. Nucl. Med. Commun. 26, 581-586 (2005).
28. Vallabhajosula, S., Kuji, I., Hamacher, K. A., Konishi, S., Kostakoglu, L., Kothari, P. A., Milowski, M. I., Nanus, D. M., Bander, N. H. and Goldsmith, S. J. Pharmacokinetics and biodistribution of 111In-and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J. Nucl. Med.: Official Publication. Soc. Nucl. Med. 46, 634-641 (2005).
29. Krausz, Y. et al. (68)Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (111)In-DTPA-Octreotide (OctreoScan (R)). Mol. Imaging Biol. 13, 583-593 (2011).
30. Luessen, H. L., deLeeuw, B. J., Langemeyer, M. W. E., deBoer, A. G., Verhoef, J. C. and Junginger, H. E. Mucoadhesive polymers in peroral peptide drug delivery. 6. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13, 1668-1672 (1996).
31. Ratcliffe, K. E., Fraser, H. M., Sellar, R., Rivier, J. and Millar, R. P. Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. Endocrinol 147, 571-579 (2006).
32. Jaeger, L. B., Banks, W. A., Varga, J. L. and Schally, A. V. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc. Natl Acad. Sci. USA 102, 12495-12500 (2005).
33. Palm, S., Enmon, R. A., Matei, C., Kolbert, K. S., Xu, S., Zanzonico, P. B., Finn, R. L., Koutcher, J. A., Larson, S. M. and Sgouros, G. Pharmacokinetics and biodistribution of (86)Y-trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J. Nucl.Med. 44, 1148-1155 (2003).
34. Deterding, T. A., Votaw, J. R., Wang, C. K., Eshima, D., Eshima, L., Keil, R., Malveaux, E., Kilts, C. D., Goodman, M. M. and Hoffman, J. M. Biodistribution and radiation dosimetry of the dopamine transporter ligand [F-18]FECNT. J. Nucl. Med. 42, 376-381 (2001).
35. Belanger, M. J., Krause, S. M., Ryan, C., Sanabria-Bohorquez, S., Li, W. P., Hamill, T. G. and Burns, H. D. Biodistribution and radiation dosimetry of [(18)F]F-PEB in nonhuman primates. Nucl. Med. Commun. 29, 915-919 (2008).
36. Tipre, D. N., Lu, J. Q., Fujita, M., Ichise, M., Vines, D. and Innis, R. B. Radiation dosimetry estimates for the PET serotonin transporter probe C-11-DASB determined from whole-body imaging in non-human primates. Nucl. Med. Commun. 25, 81-86 (2004).
37. Berger, H., Sandow, J., Heinrich, N., Albrecht, E., Kertscher, U. and Oehlke, J. Disposition of the 3Hlabeled gonadotropin-releasing hormone analog Buserelin in rats. Drug Metab. Dispos. 21, 818-822 (1993).